Eric Aaronson Image

Eric Aaronson

Chief Counsel, Corporate Affairs, Intellectual Property and Intellectual Property Enforcement

Pfizer, Inc.

Eric Aaronson is currently Chief Counsel, Corporate Affairs, Intellectual Property and Intellectual Property Enforcement for Pfizer Inc. with responsibility for counseling the company’s Corporate Affairs department along with leading the company’s patent, patent enforcement, trademark and IP policy teams.  Eric is a member of Pfizer’s Legal Division Executive Team and is currently Chair of its Development and Equity Committee with responsibility for improving diversity, inclusion and colleague talent development within the Legal Division.  Over his 23 years at Pfizer, Eric has also served as Chief Counsel for Pfizer’s Global Innovative Pharmaceutical group with responsibility for its innovative pharmaceutical business, and then Chief Counsel for Pfizer’s Essential Health Business Unit, focusing on Pfizer’s biosimilar and generic portfolios.  Before joining Pfizer in 2000, Eric worked at Kaye Scholer, LLP. He graduated from the State University of New York at Binghamton and the New York University School of Law.

Recent Articles by Eric Aaronson

Setting the Record Straight: The Truth about Patents in the Biopharmaceutical Sector

The only thing that moves quicker, disseminates further, and is repeated more often than the truth is misinformation. The more misinformation is repeated, the more challenging it becomes to distinguish truth from falsehood. A groundbreaking 1977 study termed this the “illusory truth effect”. According to the study, if “people are told something often enough, they’ll believe it.”  Simply repeating a statement makes it more likely to appear to be truthful. The impact of the illusory truth effect can be particularly harmful when those responsible for setting policy are unable to differentiate fact from fiction.